- Trials with a EudraCT protocol (143)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
143 result(s) found for: Palatability.
Displaying page 1 of 8.
EudraCT Number: 2011-004217-17 | Sponsor Protocol Number: CICL670AUS32 | Start Date*: 2011-12-09 | |||||||||||
Sponsor Name:Novartis Pharmaceuticals Corporation | |||||||||||||
Full Title: A single-arm, open-label study of the Palatability and Tolerability of Exjade Taken with Meals, with Different Liquids or Crushed and Added to Food | |||||||||||||
Medical condition: transfusional hemosiderosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2024-000583-38 | Sponsor Protocol Number: 70033093THR1011 | Start Date*: 2024-12-20 | |||||||||||
Sponsor Name:Janssen Research & Development, LLC | |||||||||||||
Full Title: Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Ris... | |||||||||||||
Medical condition: Thromboembolic Events | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001438-34 | Sponsor Protocol Number: 20-101 | Start Date*: 2005-05-23 |
Sponsor Name:McNeil Consumer and Specialty Pharmaceuticals | ||
Full Title: A Phase II, Randomized, Investigator-Blinded, Parallel-Group, Pilot Study Evaluating the Safety, Palatability and Efficacy of Four Doses of Pancrelipase Microtablets in the Treatment of Infants and... | ||
Medical condition: Cystic Fibrosis-Related Pancreatic Insufficiency and Fat Malabsorption | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002885-15 | Sponsor Protocol Number: AI424-567 | Start Date*: 2020-07-15 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-label, Randomized Crossover Study to Obtain a Preliminary Estimate of the Bioavailability of Atazanavir and Cobicistat When Administered in an Age-appropriate Fixed‑dose Combination Formula... | |||||||||||||
Medical condition: HIV in paediatric population | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002191-36 | Sponsor Protocol Number: TAK-620-1019 | Start Date*: 2022-07-18 |
Sponsor Name:Shire | ||
Full Title: A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral... | ||
Medical condition: Healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000278-13 | Sponsor Protocol Number: P16-07/BP052 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:BIOPROJET PHARMA | |||||||||||||
Full Title: Palatability testing in children of a new paediatric formulation of Racecadotril as oral suspension strawberry-flavored administered via an oral graduated syringe compared to the current formulatio... | |||||||||||||
Medical condition: Young healthy volunteers (7-12 years) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002286-36 | Sponsor Protocol Number: Sobi.NTBC-002 | Start Date*: 2012-11-19 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB | |||||||||||||
Full Title: Taste and palatability of Orfadin suspension. An open, non-controlled 3-day study in pediatric patients with hereditary tyrosinemia type 1 treated with Orfadin. | |||||||||||||
Medical condition: Hereditary tyrosinemia type 1 (HT-1) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003850-25 | Sponsor Protocol Number: PXVX-VC-200-006 | Start Date*: 2018-12-04 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:PaxVax Inc | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Prevention of cholera | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-003577-25 | Sponsor Protocol Number: 1907V921F | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Shionogi B.V. | |||||||||||||
Full Title: A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment w... | |||||||||||||
Medical condition: Opioid induced constipation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Prematurely Ended) IT (Completed) NL (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000365-12 | Sponsor Protocol Number: CAFQ056A2166 | Start Date*: 2011-04-21 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, open-label, five period, crossover study to evaluate the single dose pharmacokinetics and food effect of two pediatric AFQ056 formulations in healthy adults | ||
Medical condition: Not Applicable. This is a PK study (including evaluation of food effect). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004696-40 | Sponsor Protocol Number: PAT-PAL-404 | Start Date*: 2020-02-18 | |||||||||||
Sponsor Name:Vifor (International) Inc. | |||||||||||||
Full Title: A phase IV, randomized, double blind cross-over study to evaluate palatability of Patiromer compared to Sodium Polystyrene Sulfonate in healthy subjects | |||||||||||||
Medical condition: Treatment of hyperkalaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002969-27 | Sponsor Protocol Number: PMF104PD1-2-3/2013 | Start Date*: 2015-12-11 | |||||||||||
Sponsor Name:Alfa Wassermann S.p.A. | |||||||||||||
Full Title: A RANDOMISED, SINGLE-BLIND, ACTIVE CONTROLLED, MULTI-CENTRE TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, ACCEPTABILITY AND PALATABILITY OF PMF104 COMPARED TO A CONVENTIONAL PEG-ELECTROLYTE... | |||||||||||||
Medical condition: Need of bowel cleansing in order to perform a colonoscopy or any other diagnostic or therapeutic procedure concerning the colon. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) BE (Completed) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004420-30 | Sponsor Protocol Number: CL3-95008-002 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children aged from 2 to less than 7 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, placebo controlled mult... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) ES (Prematurely Ended) NL (Not Authorised) HU (Completed) PT (Completed) PL (Prematurely Ended) IE (Prematurely Ended) CZ (Completed) SK (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001896-63 | Sponsor Protocol Number: E3810-A001-015 | Start Date*: 2016-06-27 |
Sponsor Name:Eisai Medical Research Inc. | ||
Full Title: An Ascending Bioavailability of a New Oral Suspension of E3810 | ||
Medical condition: Bioavailability/Bioequivalence | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-002313-22 | Sponsor Protocol Number: ADV6770-A11CS | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:ADVICENNE PHARMA SA | ||||||||||||||||||
Full Title: A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance ... | ||||||||||||||||||
Medical condition: Children with chilhood absence epilepsy. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000577-22 | Sponsor Protocol Number: AKF-UMCN11.05 | Start Date*: 2012-07-17 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Palatability testing of a new paediatric formulation of valacyclovir for the prophylaxis and treatment of VZV and HSV infections in children – VALID 0 | |||||||||||||
Medical condition: Herpes virus infections, especially Herpes Simplex, Varicella Zoster and Cytomegalovirus | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002396-18 | Sponsor Protocol Number: 2015-602295-02 | Start Date*: 2015-11-30 | |||||||||||
Sponsor Name:Ethicare GmbH | |||||||||||||
Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE | |||||||||||||
Medical condition: Heart Failure due to Congenital Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000259-28 | Sponsor Protocol Number: 54179060LYM3003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma. | |||||||||||||
Medical condition: Mature B-Cell Neoplasm | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) CZ (Completed) HU (Completed) DE (Completed) NL (Completed) ES (Completed) PL (Completed) BG (Completed) Outside EU/EEA SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004419-38 | Sponsor Protocol Number: CL3-95008-001 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of bumetanide oral liquid formulation in children and adolescents aged from 7 to less than 18 years old with Autism Spectrum Disorder. A 6-month randomised, double-blind, place... | |||||||||||||
Medical condition: Autism Spectrum Disorder (ASD) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Prematurely Ended) DE (Completed) ES (Prematurely Ended) NL (Completed) HU (Completed) PT (Completed) PL (Prematurely Ended) IT (Completed) IE (Prematurely Ended) CZ (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003602-41 | Sponsor Protocol Number: 2020-012-GLOB2 | Start Date*: 2022-11-15 |
Sponsor Name:HUTCHMED Limited | ||
Full Title: AN OPEN-LABEL, MULTICENTER PHASE 1/2 STUDY OF SURUFATINIB IN COMBINATION WITH GEMCITABINE IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS | ||
Medical condition: recurrent or refractory solid tumors or lymphoma (not central nervous system) who have a known or expected dysfunction of vascular endothelial growth factor receptor-1, -2, and -3; fibroblast growt... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) DK (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
